Open-label, multicenter clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab in the treatment of patients with COVID-19 pneumonia: the BREATH-19 study.
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: SEIMC-GESIDA FOUNDATION
- Phase: II
- Execution start: 14/08/2020
- End of execution: 30/08/2020
- IP: ANA DOLORES ROMERO ORTIZ